Treatment of special populations with the atypical antipsychotics

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Atypical antipsychotics have become the treatment of choice for patients experiencing a first episode of schizophrenia. In addition, they are often prescribed for conditions such as bipolar disorder and dementia. While clinical trials have not yet established the efficacy of the atypical antipsychotics for these uses, a number of reports offer preliminary evidence that the atypical antipsychotics may be beneficial for affective disorders, substance abuse disorder, senile dementia, and pathologic aggression. Atypical agents may be particularly effective and tolerable in elderly patients who are especially susceptible to the adverse effects of conventional antipsychotic medication. Lower dosages are more necessary for the elderly than for younger adults. Current evidence suggests that clozapine is the most effective atypical antipsychotic for neuroleptic-resistant patients. Risperidone, olanzapine, and quetiapine may also be effective in a subset of these patients.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalJournal of Clinical Psychiatry
Issue numberSUPPL. 12
StatePublished - Oct 5 1998

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Treatment of special populations with the atypical antipsychotics'. Together they form a unique fingerprint.

Cite this